Atjaunināt sīkdatņu piekrišanu

Emerging Nanotechnologies in Immunology: The Design, Applications and Toxicology of Nanopharmaceuticals and Nanovaccines [Hardback]

Edited by (Professor, Department of Pharmaceutical Technology of the Faculty of Pharmacy, University of Porto, Portug), Edited by (Postdoctoral Researcher, Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Free University of Berlin, Germany)
  • Formāts: Hardback, 290 pages, height x width: 235x191 mm, weight: 770 g
  • Sērija : Micro & Nano Technologies
  • Izdošanas datums: 19-May-2018
  • Izdevniecība: Elsevier - Health Sciences Division
  • ISBN-10: 0323400167
  • ISBN-13: 9780323400169
Citas grāmatas par šo tēmu:
  • Hardback
  • Cena: 158,75 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
Emerging Nanotechnologies in Immunology: The Design, Applications and Toxicology of Nanopharmaceuticals and NanovaccinesPalielināt
  • Formāts: Hardback, 290 pages, height x width: 235x191 mm, weight: 770 g
  • Sērija : Micro & Nano Technologies
  • Izdošanas datums: 19-May-2018
  • Izdevniecība: Elsevier - Health Sciences Division
  • ISBN-10: 0323400167
  • ISBN-13: 9780323400169
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9780323400169.html

Emerging Nanotechnologies in Immunology: The Design, Applications and Toxicology of Nanopharmaceuticals and Nanovaccines aims to deliver a systematic and comprehensive review of data concerning the nature of interaction and nano-related risks between the nanopharmaceuticals currently in the pipeline of S&T development for skin, ocular and nasal drug delivery, including absorption, toxicity, and the ability to distribute after systemic exposure. The book's contributors address a representative set of the broad spectrum of nanopharmaceutics presently being used, including cationic lipid nanoparticles, polymeric PLGA, PLA nanoparticles, biomacromolecules-based nanoparticles, and other scaffolds tissue-engineered skin substitutes.

In addition, regulation and risk are also covered since the safety of these nanopharmaceuticals still represents a barrier to their wide and innovative use.

  • Provides a thorough knowledge of the safety aspects of nanopharmaceuticals currently under research
  • Focuses on the characterization and quantification of nanopharmaceutics to allow readers to understand the correlation between the nature of the materials and their potential nanotoxicological effects
  • Includes a thorough overview of legal and regulatory aspects and a discussion of the ethical issues related to the R&D of nanopharmaceuticals
List of Contributors
xi
Biography xv
Preface xvii
Chapter 1 Nanopharmaceuticals in immunology: What's new in research?
1(22)
Ranjita Shegokar
Ana R. Fernandes
Eliana B. Souto
1.1 Introduction
1(3)
1.2 Application of Nanopharmaceuticals for Disease Treatment
4(1)
1.3 Evolution of Nanopharmaceuticals for Disease Treatment
4(11)
1.3.1 Cancer
4(4)
1.3.2 Immunotherapy
8(1)
1.3.3 Vaccines
9(2)
1.3.4 HIV/AIDS
11(4)
1.3.5 Tuberculosis and Malaria
15(1)
1.4 Conclusion
15(8)
References
16(7)
Chapter 2 Skin delivery of antimicrobial peptides
23(24)
Monika Schafer-Korting
Jens Rolff
Abbreviations
24(1)
2.1 Introduction
24(1)
2.2 AMPs --- Chemistry, Antimicrobial and Antitumor Effects
25(2)
2.3 Human AMPs and Proteins
27(1)
2.3.1 Defensins
27(1)
2.3.2 Cathelicidins
28(1)
2.3.3 Psoriasin
28(1)
2.4 AMPs From Non-human Vertebrates and From Invertebrates
28(2)
2.4.1 Magainins and Temporins --- AMPs From Frogs
28(1)
2.4.2 AMPs From Insects
29(1)
2.5 AMPs Regulate Homeostasis in Healthy and Diseased Skin
30(1)
2.6 Atopic Dermatitis
30(2)
2.6.1 Atopic Dermatitis and the AMPs
30(1)
2.6.2 Reconstructed Atopic Skin --- AMPs and Bacterial Growth
31(1)
2.7 Psoriasis
32(1)
2.8 Acne
32(1)
2.9 Wound Healing/Keloid Formation
33(1)
2.10 Topical Use of AMPs
34(1)
2.11 Nanoparticle-Enhanced Peptide Penetration Into the Skin
34(2)
2.12 Penetration Enhancers for Protein Delivery
36(1)
2.13 Nanoparticle Enforced Peptide Effects
36(4)
2.13.1 Antibacterial Effects
36(2)
2.13.2 Nanoparticles for Improved Antipsoriatic Therapy
38(2)
2.14 Conclusion
40(7)
References
40(5)
Further Reading
45(2)
Chapter 3 Skin penetration of nanoparticles
47(42)
Shohreh Nafisi
Howard I. Maibach
3.1 Introduction
47(2)
3.2 Skin Structure and Function
49(5)
3.2.1 Skin Structure
49(4)
3.2.2 Derivative Structure of the Skin
53(1)
3.3 Skin Functions
54(3)
3.3.1 Mechanism of Skin Penetration
55(2)
3.4 Sources of NPs
57(18)
3.4.1 Significance of Skin Penetration Studies of NPs
58(1)
3.4.2 Factors Affecting Skin Penetration of NPs
59(16)
3.5 Conclusion
75(14)
Acknowledgement
76(1)
References
76(13)
Chapter 4 Regulatory and risk assessment perspective for core-multishell nanocarriers: A novel excipient on its way towards marketing authorization
89(14)
Margret I. More
Marcin Libera
Florian Paulus
Emanuel Fleige
Sam D. More
4.1 Core-Multishell Nanocarriers
89(3)
4.2 Regulatory Requirements for CMS Carriers as an Excipient
92(7)
4.3 Conclusion
99(4)
References
101(1)
Further Reading
102(1)
Chapter 5 Lipid nanoparticles as carriers for delivery of anti-inflammatory drugs
103(32)
Anoelka B. Kovacevic
Sergio M.C. Silva
Slavomira Doktorovova
5.1 Introduction
103(2)
5.2 Anti-inflammatory Drugs
105(5)
5.2.1 Mechanism of Inflammation
105(2)
5.2.2 Glucocorticoids
107(1)
5.2.3 Nonsteroidal Anti-inflammatory Drugs
108(2)
5.3 Challenges in Delivery of Anti-inflammatory Drugs
110(1)
5.4 Lipid Nanoparticles: Application in Delivery of Anti-inflammatory Drugs
111(9)
5.4.1 Oral Delivery
111(1)
5.4.2 Topical Delivery
112(6)
5.4.3 Ocular Delivery
118(1)
5.4.4 Pulmonary Delivery
119(1)
5.4.5 Parenteral Delivery
119(1)
5.5 Influence of Lipid Nanoparticles on Immune System---Induction of Inflammatory Reactions
120(5)
5.6 Conclusion and Perspectives
125(10)
Acknowledgments
126(1)
References
126(9)
Chapter 6 New strategies for the treatment of autoimmune diseases using nanotechnologies
135(30)
Amelia M. Silva
Joao R. Siopa
Carlos Martins-Gomes
Maria C. Teixeira
Dario J. Santos
Maria Dos Anjos Pires
Tatiana Andreani
6.1 An Overview of the Immune System in Health and Disease
135(1)
6.2 Innate and Adaptive Immune System
136(3)
6.3 Immune System and Inflammatory Response
139(1)
6.4 Immune Tolerance and Autoimmunity
139(2)
6.5 Nanotherapeutic Approaches to Treat Selected Autoimmune Diseases
141(1)
6.6 Nanocarriers for Drug Delivery and Treatment of Autoimmune Diseases
142(13)
6.6.1 Nanocarriers for Oral Insulin Delivery
145(10)
6.7 Conclusion
155(10)
References
155(10)
Chapter 7 Nanopharmaceuticals: Application in inhaler systems
165(38)
Aysu Yurdasiper
Mesut Arici
Mine Ozyazici
7.1 Nanoparticulate Drug Delivery in Pulmonary Systems
167(9)
7.2 Inhaled Drug Delivery Via Devices
176(1)
7.3 Nebulizers
176(4)
7.4 Pressurized Metered-Dose Inhalers
180(1)
7.5 Dry Powder Inhalers
181(8)
7.6 Conclusion
189(14)
References
190(13)
Chapter 8 Immunomodulatory effects of curcumin in Infectious and Non Infectious Diseases
203(30)
Ranjita Shegokar
8.1 Introduction
203(1)
8.2 Chemistry and Mechanism of Action
204(3)
8.3 Cancer Therapy
207(6)
8.3.1 Polymeric Nanoparticles
207(3)
8.3.2 Solid Dispersions
210(1)
8.3.3 Lipid Nanoparticles
210(1)
8.3.4 Liposomes
211(1)
8.3.5 Magnetic and Mucoadhesive Nanoparticles
212(1)
8.4 Malaria
213(1)
8.5 Acquired Immunodeficiency Syndrome
214(1)
8.6 Neurodegenerative Diseases
215(1)
8.7 Phototherapy
216(1)
8.8 Inflammation and Inflammatory Diseases
216(2)
8.9 Skin Diseases
218(2)
8.10 Clinical Status
220(1)
8.11 Chemical Modifications and Derivatives
221(1)
8.12 Conclusion
221(12)
References
225(8)
Chapter 9 Advances in antibiotic nanotherapy: Overcoming antimicrobial resistance
233(28)
M.C. Teixeira
E. Sanchez-Lopez
M. Espina
A.C. Calpena
Amelia M. Silva
F.J. Veiga
M.L. Garcia
Eliana B. Souto
9.1 Introduction
234(1)
9.2 Mechanisms of Antimicrobial Drug Resistance
235(4)
9.2.1 Acquired Mechanisms
236(2)
9.2.2 Intrinsic Bacteria Characteristics and Factors That Contribute to Antibiotic Resistance
238(1)
9.3 Nanoantibiotics for Infection Control: Overcoming Bacterial Drug Resistance
239(10)
9.3.1 Alteration of Efflux Pumps Activity
240(1)
9.3.2 Protection Against Enzymatic Degradation and Inactivation
241(2)
9.3.3 Antibiofilm Activity
243(2)
9.3.4 Intracellular Delivery
245(1)
9.3.5 Specific Targeting and Sustained-Release
246(2)
9.3.6 Synergistic Effect of Multidrug Complexes
248(1)
9.3.7 Infection-Activated Delivery Systems
249(1)
9.4 Advantages and Disadvantages of Nanoantibiotics
249(3)
9.5 Conclusion
252(9)
Acknowledgments
253(1)
References
253(6)
Further Reading
259(2)
Index 261
Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com)

Eliana B. Souto is Habil. Professor from the Department of Pharmaceutical Technology of the Faculty of Pharmacy of University of Porto. Prof. Souto graduated in Pharmaceutical Sciences from University of Coimbra (2000), is holder of a masters in science degree in Pharmaceutical Technology from University of Porto (2002), and PhD in Pharmaceutical Nanotechnology and Biopharmaceutics from the Institut fuer Pharmazie der Freie Universitaet Berlin, Germany (2005). Her research lines include the design, development, and characterization of new drug delivery systems to overcome biological barriers. Prof. Souto serves as Associate Editor, member of the Editorial Board, and Reviewer of several international scientific journals and has published more than 500 works (original and review papers, books and book chapters) in the field of nanosciences and nanomedicine. Prof. Souto also acts as independent expert for several national, European and international funding agencies, and as consultant for pharmaceutical industry.